查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405884

镰状细胞贫血治疗市场规模、份额、趋势分析报告：按治疗、按最终用途、按地区、细分市场预测，2024-2030 年

Sickle Cell Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Blood Transfusion, Bone Marrow Transplant), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

镰状细胞贫血治疗市场的成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球镰状细胞疾病治疗市场规模预计将达到74.2亿美元，预测期内复合年增长率为15.7%。

预计有几个因素将推动成长，包括增加研发投资、增加目标人口、提高意识计画以及有利的政府措施。据欧洲镰状细胞联合会称，欧洲约有 7 万人患有镰状细胞疾病 (SCD)。

引入有助于检测 SCD 的非侵入性且技术先进的数位技术将有助于克服与靶向镰状细胞诊断和治疗管理相关的障碍。目前正在开发的 POC 设备是基于光密度测定、侧流免疫检测和微流体电泳等技术。镰状细胞疾病诊断率的提高可能会进一步推动成长。

镰状细胞疾病的现有治疗方法通常可以缓解症状和安宁疗护。这些治疗方法通常包括输血、骨髓移植和药物治疗。然而，骨髓移植是仅推荐给少数患者的唯一可能治癒的治疗方法。此外，Global Blood Therapeutics, Inc. 的 Oxbryta、Emmaus Medical, Inc. 的 Endari 和 Agios Pharmaceuticals, Inc. 的 PYRUKYND 等新药的核准增加预计将推动市场成长。

市场参与者与政府和非政府组织之间加强合作预计将在预测期内推动市场成长。例如，2021 年 2 月，诺华公司与比尔及梅琳达盖兹基金会合作开发了一种针对镰状细胞疾病的新型基因疗法。根据协议，比尔及梅琳达盖兹基金会将提供资金支持开发治疗镰状细胞疾病的新治疗方法。

大量未满足的医疗需求、强大的管道和不断增加的患者人数是预期影响市场成长的关键因素。近年来，由于缺乏永久治疗方法以及与骨髓移植相关的风险，对镰状细胞贫血的经济有效的药物和基因治疗的需求增加。 Bluebird Bio、Bellicum Pharmaceuticals 和 Gamidacell 等公司正积极致力于开发用于治疗镰状细胞疾病的新型基因疗法药物，预计未来几年治癒率将会上升。

voxelotor、crizanlizumab、Altemia、rivipansel 等阶段研发药物预计将在预测期内推动镰状细胞疾病产业的发展。各国需要在医疗保健方面做出努力，以减轻镰状细胞疾病的经济负担，改善医疗设施的可近性，并提供早期诊断、后续治疗和安宁疗护等一系列服务。

镰状贫血治疗市场报告亮点

  • 根据治疗方法，输血领域在 2023 年占据市场主导地位。用于管理 SCD 的大量手术和主要治疗方案支撑了该细分市场的份额。
  • 按最终用途划分，医院细分市场将在 2023 年占据最大的市场占有率，因为医院已成为治疗和诊断这种​​疾病的主要中心。
  • 虽然北美在 2023 年以超过 37.87% 的份额主导全球市场，但预计亚太地区在预测期内将以最快的复合年增长率成长。
  • 市场开拓的主要参与者正在采取新产品开发、併购等多种策略，以在预测期内扩大市场占有率。

目录

第一章 研究范围和目的

第 2 章执行摘要

第三章 市场变数、趋势与范围

  • 市场体系展望
  • 镰状细胞贫血治疗的市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 镰状细胞贫血治疗市场：商业环境分析工具
    • 波特五力分析
    • PESTEL分析
  • 普及和成长前景图
  • COVID-19感染疾病对镰状细胞贫血治疗市场的影响

第四章镰镰状细胞性贫血治疗市场：治疗分析

  • 2018 年和 2030 年镰状贫血药物市场占有率分析
  • 镰状细胞性贫血治疗市场：细分仪表板：
  • 2018年至2030年治疗细分市场规模、预测、趋势分析
    • 骨髓移植
    • 输血
    • 药物治疗

镰状镰状细胞性贫血治疗市场：最终用途分析

  • 2018 年和 2030 年镰状细胞贫血症治疗最终用途市场占有率分析
  • 镰状细胞贫血症治疗最终用途市场：细分仪表板
  • 最终用途细分市场规模、预测、趋势分析，2018-2030 年
    • 医院
    • 专科诊所
    • 其他的

镰状镰状细胞性贫血治疗市场：区域分析

  • 2023 年和 2030 年按地区分類的市场占有率
  • 北美洲
    • SWOT分析
    • 北美市场，2018-2030
    • 美国
    • 加拿大
  • 欧洲
    • SWOT分析
    • 欧洲市场，2018-2030
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • SWOT分析
    • 亚太市场，2018-2030
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • SWOT分析
    • 拉丁美洲市场，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • SWOT分析
    • MEA镰状细胞疾病市场，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章竞争分析

  • 公司分类
  • 策略规划
    • 新产品发布
    • 合伙
    • 获得
    • 合作
  • 公司简介
    • Novartis AG
    • Pfizer Inc.
    • bluebird bio, Inc.
    • GlycoMimetics
    • Emmaus Medical, Inc.
    • Bristol-Myers Squibb Company
    • CRISPR Therapeutics
    • Graphite Bio, Inc.
Product Code: GVR-2-68038-442-0

Sickle Cell Disease Treatment Market Growth & Trends:

The global sickle cell disease treatment market size is expected to reach USD 7.42 billion by 2030, registering a CAGR of 15.7% during the forecast period, according to a new report by Grand View Research, Inc. Several factors including increased investments in R&D, a growing target population, increasing awareness programs, and favorable government initiatives are anticipated to drive the growth. According to the European Sickle Cell Federation, around 70 thousand people are living with sickle cell disease (SCD) in Europe.

The introduction of noninvasive, technologically advanced, and digital technologies to facilitate the detection of SCD is set to assist in overcoming the barriers associated with targeted sickle cell diagnosis and treatment management. Presently developed POC devices are based on methodologies such as densitometry, lateral flow immunoassay, and microfluidic electrophoresis. The increase in the diagnosis rate of disease will further facilitate growth.

Available treatments for sickle cell disease usually provide symptomatic relief and palliative care. These treatment methods generally include blood transfusions, bone marrow transplants, and pharmacotherapy. However, a bone marrow transplant is the only potentially curative treatment recommended only to a small percentage of patients. Moreover, increasing approval of novel drugs such as Oxbryta by Global Blood Therapeutics, Inc.;Endari by Emmaus Medical, Inc.; and PYRUKYND by Agios Pharmaceuticals, Inc. is expected to drive the market growth.

Increasing collaborations between market players and government and non-government organizations are anticipated to fuel market growth over the forecast period. For instance, in February 2021, Novartis AG and Bill & Melinda Gates Foundation collaborated to develop novel gene therapy for sickle cell disease. According to the agreement, Bill & Melinda Gates Foundation will provide funding to support the development of novel therapy to cure SKD.

High-unmet medical needs, a strong pipeline, and a growing patient pool are key factors expected to influence market growth. In recent years, demand for cost-effective drugs and gene therapies for sickle cell anemia has increased owing to the unavailability of a permanent cure and the risks associated with bone marrow transplants. Companies such as bluebird bio, Inc.; Bellicum Phamaceuticals, Inc.; and Gamida Cell are actively involved in the development of new effective gene therapies for sickle cell disease treatment, which is expected to increase the treatment rate in the coming years.

Expected launches of late-stage pipeline drugs such as voxelotor, crizanlizumab, Altemia, and rivipansel are projected to drive the sickle cell disease industry during the forecast period. Healthcare initiatives undertaken by respective economies are crucial for curbing the financial burden of the disease as well as for increasing access to healthcare facilities and providing various services for early diagnosis, subsequent treatment, and palliative care.

Sickle Cell Disease Treatment Market Report Highlights:

  • Based on treatment, the blood transfusion segment dominated the market in 2023. The high number of procedures and mostly adopted therapeutic options to manage SCD support the segment share
  • Based on end-use, the hospital segment held the largest market share in 2023 as hospitals served as primary centers for treatment and diagnosis of the disease
  • North America dominated the global market with a share of more than 37.87% in 2023, whereas the Asia Pacific region is projected to grow at the fastest CAGR over the forecast period
  • Key market players are undertaking several strategies such as new product development, mergers & acquisitions to increase their market share over the forecast period.

Table of Contents

Chapter 1 Report Scope and Objectives

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Definitions
      • 1.1.1.1 Treatment segment
      • 1.1.1.2 End-use segment
  • 1.2 Regional Scope
  • 1.3 Estimates and Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 GVR's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary research
  • 1.7 Information or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List of Secondary Sources
  • 1.11 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
    • 2.2.1 Treatment
    • 2.2.2 End-use
    • 2.2.3 Region
  • 2.3 Competitive Insights

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
  • 3.2 Sickle cell disease treatment Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Increasing prevalence of disease
      • 3.2.1.2 Awareness programs and services
      • 3.2.1.3 Presence of reimbursement policies
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Adverse effects and risks related to the treatment procedure
  • 3.3 Sickle cell disease treatment Market: Business Environment Analysis Tools
    • 3.3.1 PORTER'S Five Forces Analysis
      • 3.3.1.1 Threat of new entrants
      • 3.3.1.2 Bargaining power of suppliers
      • 3.3.1.3 Bargaining power of buyers
      • 3.3.1.4 Competitive rivalry
      • 3.3.1.5 Threat of substitutes
    • 3.3.2 PESTEL Analysis
      • 3.3.2.1 Political & Legal
      • 3.3.2.2 Economic & Social
      • 3.3.2.3 Technological
  • 3.4 Penetration & Growth Prospect Mapping
  • 3.5 Impact of COVID-19 on the sickle cell disease treatment market

Chapter 4 Sickle Cell Disease Treatment Market: Treatment Analysis

  • 4.1 Sickle Cell Disease Treatment Treatment Market Share Analysis, 2018 & 2030
  • 4.2 Sickle Cell Disease Treatment Treatment Market: Segment Dashboard:
  • 4.3 Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Treatment Segment
    • 4.3.1 Bone Marrow Transplant
      • 4.3.1.1 Bone marrow transplant market, 2018 - 2030 (USD Million)
    • 4.3.2 Blood Transfusion
      • 4.3.2.1 Blood transfusion market, 2018 - 2030 (USD Million)
    • 4.3.3 Pharmacotherapy
      • 4.3.3.1 Pharmacotherapy market, 2018 - 2030 (USD Million)

Chapter 5 Sickle Cell Disease Treatment Market: End-use Analysis

  • 5.1 Sickle Cell Disease Treatment End-use Mode Market Share Analysis, 2018 & 2030
  • 5.2 Sickle Cell Disease Treatment End-use Mode Market: Segment Dashboard
  • 5.3 Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the End-use Mode Segment
    • 5.3.1 Hospitals
      • 5.3.1.1 Hospitals market, 2018 - 2030 (USD Million)
    • 5.3.2 Specialty Clinics
      • 5.3.2.1 Specialty Clinics market, 2018 - 2030 (USD Million)
    • 5.3.3 Others
      • 5.3.3.1 Others market, 2018 - 2030 (USD Million)

Chapter 6 Sickle Cell Disease Treatment Market: Regional Analysis

  • 6.1. Sickle Cell Disease Market Share By Region, 2023 & 2030
  • 6.2. North America
    • 6.2.1. SWOT Analysis
    • 6.2.2. North America Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.2.3. U.S.
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Target Disease Prevalence
      • 6.2.3.3. Competitive Scenario
      • 6.2.3.4. Regulatory Framework
      • 6.2.3.5. U.S. Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.2.4. Canada
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Target Disease Prevalence
      • 6.2.4.3. Competitive Scenario
      • 6.2.4.4. Regulatory Framework
      • 6.2.4.5. Canada Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. SWOT Analysis
    • 6.3.2. Europe Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.3.3. UK
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Target Disease Prevalence
      • 6.3.3.3. Competitive Scenario
      • 6.3.3.4. Regulatory Framework
      • 6.3.3.5. UK Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.3.4. Germany
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Target Disease Prevalence
      • 6.3.4.3. Competitive Scenario
      • 6.3.4.4. Regulatory Framework
      • 6.3.4.5. Germany Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.3.5. France
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Target Disease Prevalence
      • 6.3.5.3. Competitive Scenario
      • 6.3.5.4. Regulatory Framework
      • 6.3.5.5. France Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.3.6. Italy
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Target Disease Prevalence
      • 6.3.6.3. Competitive Scenario
      • 6.3.6.4. Regulatory Framework
      • 6.3.6.5. Italy Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.3.7. Spain
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Target Disease Prevalence
      • 6.3.7.3. Competitive Scenario
      • 6.3.7.4. Regulatory Framework
      • 6.3.7.5. Spain Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.3.8. Denmark
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Target Disease Prevalence
      • 6.3.8.3. Competitive Scenario
      • 6.3.8.4. Regulatory Framework
      • 6.3.8.5. Denmark Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.3.9. Sweden
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Target Disease Prevalence
      • 6.3.9.3. Competitive Scenario
      • 6.3.9.4. Regulatory Framework
      • 6.3.9.5. Sweden Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.3.10. Norway
      • 6.3.10.1.Key Country Dynamics
      • 6.3.10.2.Target Disease Prevalence
      • 6.3.10.3.Competitive Scenario
      • 6.3.10.4.Regulatory Framework
      • 6.3.10.5.Norway Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. SWOT Analysis
    • 6.4.2. Asia Pacific Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Regulatory Framework
      • 6.4.3.5. Japan Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.4.4. China
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Competitive Scenario
      • 6.4.4.4. Regulatory Framework
      • 6.4.4.5. China Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.4.5. India
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Target Disease Prevalence
      • 6.4.5.3. Competitive Scenario
      • 6.4.5.4. Regulatory Framework
      • 6.4.5.5. India Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Target Disease Prevalence
      • 6.4.6.3. Competitive Scenario
      • 6.4.6.4. Regulatory Framework
      • 6.4.6.5. Australia Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Target Disease Prevalence
      • 6.4.7.3. Competitive Scenario
      • 6.4.7.4. Regulatory Framework
      • 6.4.7.5. Thailand Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.4.8. South Korea
      • 6.4.8.1. Key Country Dynamics
      • 6.4.8.2. Target Disease Prevalence
      • 6.4.8.3. Competitive Scenario
      • 6.4.8.4. Regulatory Framework
      • 6.4.8.5. South Korea Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. SWOT Analysis
    • 6.5.2. Latin America Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.5.3. Brazil
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. Regulatory Framework
      • 6.5.3.5. Brazil Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Regulatory Framework
      • 6.5.4.5. Mexico Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.5.5. Argentina
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Competitive Scenario
      • 6.5.5.4. Regulatory Framework
      • 6.5.5.5. Argentina Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. SWOT Analysis
    • 6.6.2. MEA Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.6.3. South Africa
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. Regulatory Framework
      • 6.6.3.5. South Africa Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.6.4. Saudi Arabia
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. Regulatory Framework
      • 6.6.4.5. Saudi Arabia Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.6.5. UAE
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Regulatory Framework
      • 6.6.5.5. UAE Sickle Cell Disease Market, 2018 - 2030 (USD Million)
    • 6.6.6. Kuwait
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Regulatory Framework
      • 6.6.6.5. Kuwait Sickle Cell Disease Market, 2018 - 2030 (USD Million)

Chapter 7 Competitive Analysis

  • 7.1 Company Categorization
  • 7.2 Strategy Mapping
    • 7.2.1 New product launch
    • 7.2.2 Partnerships
    • 7.2.3 Acquisition
    • 7.2.4 Collaboration
  • 7.3 Company Profiles
    • 7.3.1 Novartis AG
      • 7.3.1.1 Company overview
      • 7.3.1.2 Financial performance
      • 7.3.1.3 Product benchmarking
      • 7.3.1.4 Strategic initiatives
    • 7.3.2 Pfizer Inc.
      • 7.3.2.1 Company overview
      • 7.3.2.2 Financial performance
      • 7.3.2.3 Product benchmarking
      • 7.3.2.4 Strategic initiatives
    • 7.3.3 bluebird bio, Inc.
      • 7.3.3.1 Company overview
      • 7.3.3.2 Financial performance
      • 7.3.3.3 Product benchmarking
      • 7.3.3.4 Strategic initiatives
    • 7.3.4 GlycoMimetics
      • 7.3.4.1 Company overview
      • 7.3.4.2 Financial performance
      • 7.3.4.3 Product benchmarking
      • 7.3.4.4 Strategic initiatives
    • 7.3.5 Emmaus Medical, Inc.
      • 7.3.5.1 Company overview
      • 7.3.5.2 Financial performance
      • 7.3.5.3 Product benchmarking
      • 7.3.5.4 Strategic initiatives
    • 7.3.6 Bristol-Myers Squibb Company
      • 7.3.6.1 Company overview
      • 7.3.6.2 Financial performance
      • 7.3.6.3 Product benchmarking
      • 7.3.6.4 Strategic initiatives
    • 7.3.7 CRISPR Therapeutics
      • 7.3.7.1 Company overview
      • 7.3.7.2 Financial performance
      • 7.3.7.3 Product benchmarking
      • 7.3.7.4 Strategic initiatives
    • 7.3.8 Graphite Bio, Inc.
      • 7.3.8.1 Company overview
      • 7.3.8.2 Financial performance
      • 7.3.8.3 Product benchmarking
      • 7.3.8.4 Strategic initiatives

List of Tables

  • Table 1 North America sickle cell disease treatment market, by country, 2018 - 2030 (USD Million)
  • Table 2 North America sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 3 North America Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 4 U.S. sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 5 U.S. Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 6 Canada sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 7 Canada Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 8 Europe sickle cell disease treatment market, by country, 2018 - 2030 (USD Million)
  • Table 9 Europe sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 Europe Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 11 UK sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 12 UK Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 13 Germany sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 14 Germany Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 15 France sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 16 France Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 17 Italy sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 18 Italy Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 19 Spain sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 20 Spain Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 21 Denmark sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 22 Denmark Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 23 Sweden sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 24 Sweden Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 25 Norway sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 26 Norway Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 27 Asia Pacific sickle cell disease treatment market, by country, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 30 Japan sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 31 Japan Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 32 China sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 33 China Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 34 India sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 35 India Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 36 Australia sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 37 Australia Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 38 South Korea sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 39 South Korea Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 40 Thailand sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 41 Thailand Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 42 Latin America sickle cell disease treatment market, by country, 2018 - 2030 (USD Million)
  • Table 43 Latin America sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 44 Latin America Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 45 Brazil sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 46 Brazil Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 47 Mexico sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 48 Mexico Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 49 Argentina sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 50 Argentina Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 51 MEA sickle cell disease treatment market, by country, 2018 - 2030 (USD Million)
  • Table 52 MEA sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 53 MEA Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 54 South Africa sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 55 South Africa Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 58 UAE sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 59 UAE Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
  • Table 60 Kuwait sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 61 Kuwait Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Value chain-based sizing & forecasting
  • Fig. 4 QFD modeling for market share assessment
  • Fig. 5 Market summary, 2023
  • Fig. 6 Market trends & outlook
  • Fig. 7 Market segmentation & scope
  • Fig. 8 Market driver relevance analysis (Current & future impact)
  • Fig. 9 Market restrain relevance analysis (Current & future impact)
  • Fig. 10 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 11 Porter's Five Forces Analysis
  • Fig. 12 Sickle cell disease treatment market treatment outlook key takeaways
  • Fig. 13 Sickle cell disease treatment market: Treatment movement analysis
  • Fig. 14 Global bone marrow transplant market, 2018 - 2030 (USD Million)
  • Fig. 15 Global blood transfusion market, 2018 - 2030 (USD Million)
  • Fig. 16 Global pharmacotherapy market, 2018 - 2030 (USD Million)
  • Fig. 17 Sickle cell disease treatment market End-use outlook key takeaways
  • Fig. 18 Sickle cell disease treatment market: End-use movement analysis
  • Fig. 19 Global Hospitals market, 2018 - 2030 (USD Million)
  • Fig. 20 Global Specialty Clinics market, 2018 - 2030 (USD Million)
  • Fig. 21 Global other market, 2018 - 2030 (USD Million)
  • Fig. 22 Regional marketplace: Key takeaways
  • Fig. 23 Regional marketplace: Key takeaways
  • Fig. 24 North America sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Key country dynamics
  • Fig. 26 U.S. sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Key country dynamics
  • Fig. 28 Canada sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Europe sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Key country dynamics
  • Fig. 31 UK sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Key country dynamics
  • Fig. 33 Germany sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Key country dynamics
  • Fig. 35 France sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Key country dynamics
  • Fig. 37 Spain sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Key country dynamics
  • Fig. 39 Italy sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 Denmark sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Sweden sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Norway sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Rest of Europe sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD, Million)
  • Fig. 47 Asia Pacific sickle cell disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Japan sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 China sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 India sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 South Korea sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea reimbursement scenario
  • Fig. 57 Key country dynamics
  • Fig. 58 Australia sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Thailand sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Rest of Asia Pacific sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Latin America sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Brazil sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Mexico sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Argentina sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Rest of Latin America sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 MEA sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 South Africa sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Saudi Arabia sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 UAE sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Kuwait sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Rest of MEA sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key company categorization
  • Fig. 81 Company categorization
  • Fig. 82 Company market share analysis, 2023
  • Fig. 83 Strategic framework